CoChat

Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study

Open access
Liang, Sophie Hsin-Yi, Yang, Yao-Hsu, Kuo, Ting-Yu, Liao, Yin-To, Lin, Tzu-Chin, Lee, Yena, McIntyre, Roger S., Kelsen, Brent A., Wang, Tsu-Nai, Chen, Vincent Chin-Hung · 2018 · Research in Developmental Disabilities
Cited by 58

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) youths have increased suicide risk. Nevertheless, the beneficial effects of methylphenidate (MPH) on suicide attempt have received relatively little attention. AIMS: To investigate the MPH usage and the risk of suicide attempt among ADHD youths. METHODS: We identified 84,898 youths less than 18 years old with ADHD diagnosis between 1997 and 2013 from National Health Insurance, and examined whether MPH use affected suicide attempt risk using Cox proportional-hazards models. OUTCOME AND RESULTS: Among ADHD youths, reduction of suicide risk was found in patients prescribed 90-180days of MPH after adjusting for confounding factors (hazard ratio (HR): 0.41, 95% confidence interval (CI): 0.19-0.90) and a greater reduction in those prescribed more than 180days of MPH (HR: 0.28, 95% CI: 0.17-0.48). CONCLUSIONS AND IMPLICATIONS: We observed a 59% suicide attempt risk reduction among ADHD youths prescribed between 90 and 180days and a 72% risk reduction in those prescribed more than 180days of MPH. The protective benefit observed by the group prescribed MPH for longer duration underscores the importance of psychoeducation and compliance enhancement as part of ADHD management. Indication bias is identified as a limitation of this study, and future self-case control study to investigate the association between suicide attempt and ADHD medication is suggested. WHAT THIS PAPER ADDS: This nationwide population-based cohort study showed that among ADHD youths, reduction of suicide risk was observed in patients prescribed MPH for duration 90days and longer, underscoring the importance of appropriate ADHD pharmacotherapy and enhancing drug compliance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ridd.2017.10.023

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 26

  1. Allely, 2014, The association of ADHD symptoms to self-harm behaviours: A systematic PRISMA review, BMC Psychiatry, 14, 133, 10.1186/1471-244X-14-133 · DOI · Paper page
  2. Bangs, 2014, Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine, Journal of Child and Adolescent Psychopharmacology, 24, 426, 10.1089/cap.2014.0005 · DOI · Paper page
  3. Bridge, 2006, Adolescent suicide and suicidal behavior, Journal of Child Psychology and Psychiatry, 47, 372, 10.1111/j.1469-7610.2006.01615.x · DOI · Paper page
  4. Buitelaar, 2010, Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: A review of the potential benefits of long-acting stimulants, European Child and Adolescent Psychiatry, 19, 325, 10.1007/s00787-009-0056-1 · DOI · Paper page
  5. Chou, 2014, Attention-deficit-hyperactivity disorder increases risk of bone fracture: A population-based cohort study, Developmental Medicine & Child Neurology, 56, 1111, 10.1111/dmcn.12501 · DOI · Paper page
  6. Chronis-Tuscano, 2010, Very early predictors of adolescent depression and suicide attempts in children with attention-deficit/hyperactivity disorder, Archives of General Psychiatry, 67, 1044, 10.1001/archgenpsychiatry.2010.127 · DOI · Paper page
  7. Clemow, 2015, Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients, Journal of Psychopharmacology, 29, 1221, 10.1177/0269881115602489 · DOI · Paper page
  8. Faraone, 2007, Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion, Journal of Clinical Psychiatry, 68, 15
  9. Gajria, 2014, Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder—A systematic literature review, Neuropsychiatric Disease and Treatment, 10, 1543
  10. Gau, 2008, National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan, Journal of Clininical Psychiatry, 69, 131, 10.4088/JCP.v69n0118 · DOI · Paper page
  11. Gazer-Snitovsky, 2015, High familial correlation in methylphenidate response and side effect profile, Journal of Attention Disorders, 10.1177/1087054715580844 · DOI
  12. Golden, 2006, Nonepileptic uses of antiepileptic drugs in children and adolescents, Pediatric Neurology, 34, 421, 10.1016/j.pediatrneurol.2005.08.017 · DOI
  13. Hurtig, 2012, Suicidal and self-harm behaviour associated with adolescent attention deficit hyperactivity disorder—A study in the Northern Finland Birth Cohort 1986, Nordic Journal of Psychiatry, 66, 320, 10.3109/08039488.2011.644806 · DOI · Paper page
  14. Impey, 2012, Completed suicide, ideation and attempt in attention deficit hyperactivity disorder, Acta Psychiatrica Scandinavica, 125, 93, 10.1111/j.1600-0447.2011.01798.x · DOI · Paper page
  15. Landmark, 2009, Antiepileptic drugs in epilepsy and other disorders—A population-based study of prescriptions, Epilepsy Research, 87, 31, 10.1016/j.eplepsyres.2009.07.005 · DOI
  16. Lee, 2016, Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: A nationwide population-based study in Taiwan, Journal of Affective Disorders, 189, 110, 10.1016/j.jad.2015.09.015 · DOI
  17. Leon, 2012, Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: A 30-year observational study, The American Journal of Psychiatry, 169, 285, 10.1176/appi.ajp.2011.11060948 · DOI · Paper page
  18. Markowitz, 2001, Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder, Clinical Pharmacokinetics, 40, 753, 10.2165/00003088-200140100-00004 · DOI · Paper page
  19. Meszaros, 2017, Self-injury and externalizing pathology: A systematic literature review, BMC Psychiatry, 17, 160, 10.1186/s12888-017-1326-y · DOI
  20. Olesen, 2010, Antiepileptic drugs and risk of suicide: A nationwide study, Pharmacoepidemiology and Drug Safety, 19, 518, 10.1002/pds.1932 · DOI
  21. Paternite, 1999, Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes, Journal of Child and Adolescent Psychopharmacology, 9, 169, 10.1089/cap.1999.9.169 · DOI · Paper page
  22. Patorno, 2010, Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death, JAMA: The Journal of the American Medical Association, 303, 1401, 10.1001/jama.2010.410 · DOI · Paper page
  23. Søndergård, 2008, Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide, Bipolar Disorders, 10, 87, 10.1111/j.1399-5618.2008.00464.x · DOI · Paper page
  24. Savill, 2012, Child and Adolescent Psychiatry and Mental Health, 6
  25. Vijayakumar, 2005, Suicide and mental disorders in Asia, International Review of Psychiatry, 17, 109, 10.1080/09540260500074735 · DOI · Paper page
  26. Wilens, 2002, Attention deficit/hyperactivity disorder across the lifespan, Annual Review of Medicine, 53, 113, 10.1146/annurev.med.53.082901.103945 · DOI · Paper page

Cited by

See all 58

Metadata

Authors
Liang, S. H.-Y., Yang, Y.-H., Kuo, T.-Y., Liao, Y.-T., Lin, T.-C., Lee, Y., McIntyre, R. S., Kelsen, B. A., Wang, T.-N., & Chen, V. C.-H.
Venue
Research in Developmental Disabilities
Publisher
Elsevier BV
Published
2018-01
Volume
72
Pages
96-105
ISSN
0891-4222 (ISSN-L)
OpenAlex
W2767261087
Cited by
58
References
17
FWCI
4.78
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Ministry of Science and Technology, Taiwan, ROC (102-2314-B-040-004-MY3)
  • Chang Gung Medical Foundation, Chiayi Chang Gung Memorial Hospital, Taiwan, ROC (CMRPG6E0261)
  • Chang Gung Memorial Hospital

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.